Current Collaborations
PepTcell has entered into a major contract with a private biotechnology company that will enable PepTcell to take it's current pipeline of vaccines to Phase II human trials.
PepTcell and Gador have entered into an R&D collaboration to develop a novel T-cell vaccine for Chagas disease, a neglected tropical disease with no adequate treatment or vaccination.
PepTcell has taken a 75% shareholding in Biocopea Limited with the balance of the shares held by Robin Bannister. Robin previously co-founded the very successful Arakis. Biocopea modifies and reprofiles existing pharmacopeia drugs.